VBI Vaccines (VBIV) Receives Daily Media Sentiment Rating of 0.00

Press coverage about VBI Vaccines (NASDAQ:VBIV) has been trending somewhat negative on Saturday, according to Accern. The research group identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. VBI Vaccines earned a media sentiment score of 0.00 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 45.5013696588427 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

VBI Vaccines (VBIV) traded up $0.11 during trading hours on Friday, hitting $3.76. The stock had a trading volume of 119,849 shares, compared to its average volume of 111,204. The firm has a market capitalization of $232.89, a price-to-earnings ratio of -5.15 and a beta of 1.62. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.97 and a current ratio of 1.03. VBI Vaccines has a 1-year low of $3.04 and a 1-year high of $6.60.

A number of brokerages have weighed in on VBIV. Zacks Investment Research upgraded VBI Vaccines from a “hold” rating to a “buy” rating and set a $5.25 price objective for the company in a research note on Saturday, December 23rd. BidaskClub cut VBI Vaccines from a “buy” rating to a “hold” rating in a research note on Thursday, December 7th. BMO Capital Markets began coverage on VBI Vaccines in a research note on Wednesday, November 15th. They issued an “outperform” rating and a $11.00 price objective for the company. Finally, Canaccord Genuity began coverage on VBI Vaccines in a research note on Wednesday, November 1st. They issued a “buy” rating and a $10.00 price objective for the company. Two research analysts have rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $8.75.

In related news, CEO Jeff Baxter bought 15,000 shares of the company’s stock in a transaction dated Tuesday, November 28th. The shares were acquired at an average price of $4.75 per share, with a total value of $71,250.00. Following the completion of the acquisition, the chief executive officer now owns 135,255 shares in the company, valued at approximately $642,461.25. The transaction was disclosed in a document filed with the SEC, which is available through this link. Insiders own 54.50% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “VBI Vaccines (VBIV) Receives Daily Media Sentiment Rating of 0.00” was originally published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US and international copyright and trademark laws. The correct version of this piece of content can be read at https://www.chaffeybreeze.com/2018/02/17/vbi-vaccines-vbiv-receives-daily-media-sentiment-rating-of-0-00.html.

VBI Vaccines Company Profile

VBI Vaccines Inc, formerly SciVac Therapeutics Inc, is a biotechnology company. The Company is engaged in developing various technologies that focus on vaccine protection. It has developed an enveloped virus like particle (eVLP) vaccine platform that allows for the design of enveloped VLP vaccines. It is involved in various projects related to human cytomegalovirus (CMV) and other antigens.

Insider Buying and Selling by Quarter for VBI Vaccines (NASDAQ:VBIV)

Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply